Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor

European Neuropsychopharmacology

Volumn 23, Issue 7, 2013, Pages 728-741

  Xue, Rui ^a   Jin, Zeng Liang ^a,b   Chen, Hong Xia ^a   Yuan, Li ^a   He, Xin Hua ^a   Zhang, Yan Ping ^a   Meng, Yong Gang ^a   Xu, Jiang Ping ^b   Zheng, Jian Quan ^a   Zhong, Bo Hua ^a   Li, Yun Feng ^a   Zhang, You Zhi ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Animal models; Antidepressants; Cytotoxicity test; Monoamine transporter binding test; Monoamine uptake test; Serotonin and norepinephrine uptake inhibitors

Indexed keywords

071031 B; DULOXETINE; FLUOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN CORTEX; CELL LINE; CELL STRAIN HEPG2; CHRONIC STRESS; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DEPRESSION; DRUG BINDING; DRUG EFFICACY; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LOCOMOTION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT; SYNAPTOSOME; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZODIOXOLES; CELLS, CULTURED; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES; THIOPHENES;

EID: 84878845013     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.06.001     Document Type: Article

References (58)

1. An L., Zhang Y.Z., Yu N.J., Liu X.M., Zhao N., Yuan L., Li Y.F. Role for serotonin in the antidepressant-like effects of a flavonoid extract of Xiaobuxin-Tang. Pharmacol. Biochem. Behav. 2008, 89:572-580.
2. Anderson I.M. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 1998, 7:11-17.
3. Anderson I.M. Meta-analytical studies on new antidepressants. Br. Med. Bull. 2001, 57:161-178.
4. Artaiz I., Zazpe A., Innerárity A., Del Olmo E., Díaz A., Ruiz-Ortega J.A., Castro E., Pena R., Labeaga L., Pazos A., Orjales A. Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties. Psychopharmacology (Berl) 2005, 182:400-413.
5. Bliss C.I. Statistics in Biology 1967, McGraw-Hill Book Company, New York.
6. Bodnoff S.R., Suranyi-Cadotte B., Aitken D.H., Quirion R., Meaney M.J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 1988, 95:298-302.
7. Bondi C.O., Rodriguez G., Gould G.G., Frazer A., Morilak D.A. Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharmacology 2008, 33:320-331.
8. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci. Biobehav. Rev. 1995, 19:377-395.
9. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology 1988, 94:147-160.
10. Bymaster F.P., Beedle E.E., Findlay J., Gallagher P.T., Krushinski J.H., Mitchell S., Robertson D.W., Thompson D.C., Wallace L., Wong D.T. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett. 2003, 13:4477-4480.
11. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Luecke S.K., Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25:871-880.
12. Bymaster F.P., Lee T.C., Knadler M.P., Detke M.J., Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des. 2005, 11:1475-1493.
13. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
14. Crema L., Schlabitz M., Tagliari B., Cunha A., Simão F., Krolow R., Pettenuzzo L., Salbego C., Vendite D., Wyse A.T., Dalmaz C. Na+, K+ ATPase activity is reduced in amygdala of rats with chronic stress-induced anxiety-like behavior. Neurochem. Res. 2010, 35:1787-1795.
15. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends. Pharmacol. Sci. 2002, 23:238-245.
16. Danish University Antidepressant Group Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986, 90:131-138.
17. Danish University Antidepressant Group Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1990, 18:289-299.
18. Davis W.A. The history of Marsilid. J. Clin. Exp. Psychopathol. 1958, 19:1-10.
19. Delgado P.L. Common pathways of depression and pain. J. Clin. Psychiatry 2004, 65:16-19.
20. DeSanty K.P., Amabile C.M. Antidepressant-induced liver injury. Ann. Pharmacother. 2007, 41:1201-1211.
21. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
22. Doherty M.D., Cohen G.M., Smith M.T. Mechanisms of toxic injury to isolated hepatocytes by 1-naphthol. Biochem. Pharmacol. 1984, 33:543-549.
23. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann. Med. 2000, 32:305-316.
24. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 2004, 24:389-399.
25. 3H]GBR-12935 binding in brain: a radioligand for selective labelling of the dopamine transport complex. J. Neurochem. 1986, 46:1272-1276.
26. Katz R.J., Roth K.A., Carroll B.J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci. Biobehav. Rev. 1981, 5:247-251.
27. Klerman G.L., Cole J.O. Clinical pharmacology of imipramine and related antidepressant compounds. Int. J. Psychiatry 1967, 3:267-304.
28. Koch S., Hemrick-Luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., Perry K.W., Bymaster F.P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003, 45:935-944.
29. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry 1958, 115:459-464.
30. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997, 8:523-532.
31. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
32. Millan M.J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009, 6:53-77.
33. Millan M.J., Dekeyne A., Papp M., La Rochelle C.D., MacSweeny C., Peglion J.L., Brocco M. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 2001, 298:581-591.
34. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., Peglion J.L. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 2001, 298:565-580.
35. Mineur Y.S., Belzung C., Crusio W.E. Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav. Brain Res. 2006, 175:43-50.
36. Nelson J.C., Mazure C.M., Bowens M.B., Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 1991, 48:303-307.
37. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 2002, 17:S1-S12.
38. Page M.E., Detke M.J., Dalvi A., Kirby L.G., Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999, 147:162-167.
39. Papp M., Moryl E., Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur. J. Pharmacol. 1996, 296:129-136.
40. Petit-Demouliere B., Chenu F., Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005, 177:245-255.
41. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressive treatments. Eur. J. Pharmacol. 1978, 47:379-391.
42. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
43. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal modelsindicative of antidepressant activity. Psychopharmacology (Berl) 1998, 138:1-8.
44. Rénéric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998, 136:190-197.
45. Shelton R.C., Tomarken A.J. Can recovery from depression be achieved?. Psychiatr. Serv. 2001, 52:1469-1478.
46. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS. Spectr. 2005, 10:732-747.
47. Staiger T.O., Gaster B., Sullivan M.D., Deyo R.A. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976) 2003, 28:2540-2545.
48. Steffens D.C., Krishnan K.R., Helms M.J. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress. Anxiety 1997, 6:10-18.
49. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
50. Tanaka M., Telegdy G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull. 2008, 75:509-512.
51. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001, 178:234-241.
52. Thase M.E., Pritchett Y.L., Ossanna M.J., Swindle R.W., Xu J., Detke M.J. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J. Clin. Psychopharm. 2007, 27:672-676.
53. Wernicke J., Pangallo B., Wang F., Murray I., Henck J.W., Knadler M.P., D'Souza D.N., Uetrecht J.P. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr. Drug. Saf. 2008, 3:132-142.
54. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
55. Wong D.T., Bymaster F.P. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?. Prog. Drug. Res. 2002, 58:169-222.
56. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2001, 2:343-351.
57. Xue R., Xu X.D., Li N.M., Zhang Y.Z., Li Y.F. Pharmacodynamic and toxicological evaluation of duloxetin. Chin. Pharmacol. Bull. 2010, 26:421-425.
58. Zhang Y.P., Xue R., He X.H., Meng Y.G., Zhang Y.Z., Zhong B.H. Design, synthesis and antidepressive activity of duloxetine derivatives. Yao Xue Xue Bao 2010, 45:869-873.